Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-19T06:30:36.981Z Has data issue: false hasContentIssue false

18 - Exploring the Earliest Steps in Metastasis: The Pre-metastatic Niche

from SYSTEMIC FACTORS

Published online by Cambridge University Press:  05 June 2012

Marianna Papaspyridonos
Affiliation:
Weill Cornell Medical College, United States
David Lyden
Affiliation:
Weill Cornell Medical College, United States
Rosandra N. Kaplan
Affiliation:
Weill Cornell Medical College, United States
David Lyden
Affiliation:
Weill Cornell Medical College, New York
Danny R. Welch
Affiliation:
Weill Cornell Medical College, New York
Bethan Psaila
Affiliation:
Imperial College of Medicine, London
Get access

Summary

Even though significant advances have been made in recent years in the treatment of localized malignancies, metastatic disease remains the primary cause of morbidity and mortality in cancer. Steven Paget's “seed and soil” hypothesis for metastasis first set forth the concept that a nutritive microenvironment is required to enable the engraftment of disseminating malignant cells in distant tissues. Since his observation more than one hundred years ago, our understanding of the microenvironment at the primary tumor site has expanded. However, the pathophysiology of the local cellular context, or “niche,” at distant metastatic sites that addresses Paget's original hypothesis has not been a focus of intensive research until very recently.

Of the millions of cancer cells that enter the circulatory system, very few will successfully engraft, survive, and proliferate at secondary sites. The well-documented inefficiency of the metastatic process is thought to be the result of the inability of the vast majority of disseminating cells to successfully initiate tumor growth at distant sites. The efficiency of survival and proliferation of tumor cells after arrival at these sites is likely to be a major factor in determining whether metastatic growth is successful and is thought to require a receptive microenvironment at the destination site.

In stem cell biology, the “niche” describes the specialized microenvironment that supports stem cell maintenance and controls the balance between proliferation and quiescence of the stem cells.

Type
Chapter
Information
Cancer Metastasis
Biologic Basis and Therapeutics
, pp. 199 - 203
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Weiss, L (1990) Metastatic inefficiency. Adv Cancer Res. 54: 159–211.CrossRefGoogle ScholarPubMed
Weiss, L (1980) Cancer cell traffic from the lungs to the liver: an example of metastatic inefficiency. Int J Cancer. 25: 385–92.CrossRefGoogle ScholarPubMed
Fidler, IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3: 453–8.CrossRefGoogle ScholarPubMed
Liotta, , Kohn, EC (2001) The microenvironment of the tumour-host interface. Nature. 411: 375–9.CrossRefGoogle ScholarPubMed
Chambers, AF, Groom, AC, MacDonald, IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2: 563–72.CrossRefGoogle ScholarPubMed
Schofield, R (1978) The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 4: 7–25.Google ScholarPubMed
Hiratsuka, S et al. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2: 289–300.CrossRefGoogle ScholarPubMed
Kaplan, RN et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438: 820–7.CrossRefGoogle ScholarPubMed
Hiratsuka, S, Watanabe, A, Aburatani, H, Maru, Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 8: 1369–75.CrossRefGoogle ScholarPubMed
Condeelis, J, Pollard, JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124: 263–6.CrossRefGoogle ScholarPubMed
Erler, JT et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15: 35–44.CrossRefGoogle ScholarPubMed
Hiratsuka, S et al. (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 10: 1349–55.CrossRefGoogle ScholarPubMed
Kagan, HM, Li, W (2003) Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 88: 660–72.CrossRefGoogle ScholarPubMed
Gao, D et al. (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 319: 195–8.CrossRefGoogle ScholarPubMed
Kaplan, RN, Rafii, S, Lyden, D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res. 66: 11089–93.CrossRefGoogle ScholarPubMed
Orimo, A et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121: 335–48.CrossRefGoogle ScholarPubMed
Lin, EY, Nguyen, AV, Russell, RG, Pollard, JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy [see comment]. J Exp Med. 193: 727–40.CrossRefGoogle Scholar
Gabrilovich, D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 4: 941–52.CrossRefGoogle ScholarPubMed
Melani, C, Chiodoni, C, Forni, G, Colombo, MP (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 102: 2138–45.CrossRefGoogle ScholarPubMed
Kusmartsev, S, Nefedova, Y, Yoder, D, Gabrilovich, DI (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 172: 989–99.CrossRefGoogle ScholarPubMed
Bronte, V, Serafini, P, Apolloni, E, Zanovello, P (2001) Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 24: 431–46.CrossRefGoogle ScholarPubMed
Sawanobori, Y et al. (2008) Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 111: 5457–66.CrossRefGoogle ScholarPubMed
Almand, B et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 166: 678–89.CrossRefGoogle Scholar
Mirza, N et al. (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66: 9299–307.CrossRefGoogle ScholarPubMed
Liu, C et al. (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 109: 4336–42.CrossRefGoogle ScholarPubMed
Serafini, P, Borrello, I, Bronte, V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 16: 53–65.CrossRefGoogle ScholarPubMed
Liu, Y et al. (2003) Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol. 170: 5064–74.CrossRefGoogle ScholarPubMed
Balkwill, F, Mantovani, A (2001) Inflammation and cancer: back to Virchow?Lancet. 357: 539–45.CrossRefGoogle ScholarPubMed
Kusmartsev, S, Gabrilovich, DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 174: 4880–91.CrossRefGoogle ScholarPubMed
Lin, EY, Pollard, JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67: 5064–6.CrossRefGoogle ScholarPubMed
Gabrilovich, DI et al. (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67: 425; author reply 426.CrossRefGoogle ScholarPubMed
Fricke, I et al. (2007) Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 13: 4840–8.CrossRefGoogle Scholar
Shojaei, F et al. (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 25: 911–20.CrossRefGoogle ScholarPubMed
Kusmartsev, S, Gabrilovich, DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 25: 323–31.CrossRefGoogle Scholar
Gabrilovich, DI, Nagaraj, S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9: 162–74.CrossRefGoogle ScholarPubMed
Cheng, P et al. (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 205: 2235–49.CrossRefGoogle ScholarPubMed
Leukert, N et al. (2006) Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol. 359: 961–72.CrossRefGoogle ScholarPubMed
Kim, S et al. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 457: 102–6.CrossRefGoogle ScholarPubMed
Isogai, Z et al. (1996) 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res. 56: 3902–8.Google ScholarPubMed
Pirinen, R et al. (2005) Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol. 36: 44–50.CrossRefGoogle ScholarPubMed
Hurwitz, H (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer. 4 Suppl 2: S62–S8.CrossRefGoogle Scholar
Kosaka, Y et al. (2007). Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood. Br J Cancer. 96: 1723–8.CrossRefGoogle Scholar
Mimori, K et al. (2008) Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 14: 2609–16.CrossRefGoogle ScholarPubMed
Fujita, K et al. (2009) Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Sci. 100: 1047–50.CrossRefGoogle ScholarPubMed
Okita, NT et al. (2009) Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 39: 595–600.CrossRefGoogle ScholarPubMed
Kusmartsev, S et al. (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 181: 346–53.CrossRefGoogle ScholarPubMed
Yamamoto, M et al. (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68: 9754–62.CrossRefGoogle ScholarPubMed
Kusmartsev, S et al. (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441–9.Google ScholarPubMed
Nefedova, Y et al. (2007) Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67: 11021–8.CrossRefGoogle ScholarPubMed
Suzuki, E, Kapoor, V, Jassar, AS, Kaiser, LR, Albelda, SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11: 6713–21.CrossRefGoogle ScholarPubMed
Ko, HJ et al. (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67: 7477–86.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×